针对慢性髓性白血病的氨酸激酶抑制剂剂量优化
Jiali Chen1,2, Yidan Zhu1,3, Yinyu Zhao1,3
1Department of Pharmacy, Peking University People's Hospital, Beijing, People's Republic of China.
Clinical pharmacology : advances and applications
|August 5, 2025
概括
为慢性髓性白血病 (CML) 优化氨酸激酶抑制剂 (TKI) 剂量可以减少不良事件并改善生活质量. 减少剂量是安全有效的,可能有助于无治疗缓解 (TFR) 的尝试.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学 是一个学科.
- 血液学 血液学 血液学
背景情况:
- 对于较新的癌症疗法,如氨酸激酶抑制剂 (TKI),最大耐受剂量模型已经过时了.
- 慢性髓性白血病 (CML) 患者的TKIs改善了生存率,但可能导致不良事件并影响生活质量.
- 长期使用TCI带来了挑战,包括毒性,经济负担和降低患者生活质量.
研究的目的:
- 对所有已批准的TKI在CML治疗中的剂量优化策略进行审查和分类.
- 探索TKI治疗的剂量优化,包括在无治疗缓解 (TFR) 尝试之前的方法.
- 讨论治疗药物监测在TKI剂量优化中的作用及其对生活质量的影响.
主要方法:
- 临床试验和真实世界研究对TKI在CML中剂量优化的系统审查.
- 在不同治疗阶段和各种TKI (imatinib,dasatinib,nilotinib,bosutinib,ponatinib,asciminib,radotinib) 中对剂量优化策略的分类.
- 对TKI剂量调整的分析,特别是为无治疗缓解 (TFR) 的准备.
主要成果:
- 对于大多数CML患者来说,TKIs的剂量降低通常是可行的和安全的.
- 优化的TKI剂量可以保持治疗疗效,同时减轻不良事件.
- 剂量优化可以减轻财务负担,提高患者报告的生活质量.
结论:
- 对TKIs的剂量优化是管理CML的关键策略.
- 优化的TKI治疗改善了患者的结果,生活质量,并可以促进TFR.
- 治疗药物监测可能在个性化的TKI剂量调整中发挥作用.
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:11Renal Failure: Dose Adjustments
158
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
158
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
258
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
258